Singapore’s Health Sciences Authority (HSA) has awarded conditional approval for Gilead Sciences Singapore’s experimental antiviral drug remdesivir, under the brand name Veklury, to treat adults with Covid-19.

The drug is indicated for patients with oxygen saturation less than or equal to 94%, as well as those who need supplemental oxygen or intensive breathing support, including invasive mechanical ventilation.

HSA is collaborating with the Ministry of Health to identify the subcategory of patients who could benefit from this drug.